Skip to main
NUVL

Nuvalent (NUVL) Stock Forecast & Price Target

Nuvalent (NUVL) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 16%
Buy 32%
Hold 53%
Sell 0%
Strong Sell 0%

Bulls say

Nuvalent is a promising clinical-stage biopharmaceutical company with a strong portfolio of small molecule therapies targeting key oncogenic drivers in different types of cancer. Its lead assets, zidesamtinib and neladalkib, have shown promising efficacy, tolerability, and resistance mutation coverage in clinical trials, positioning them for potential launches in 2026. Furthermore, Nuvalent has been chosen as an acquisition target by GlaxoSmithKline, further validating the strategic value of its assets. However, as with any investment in the biotechnology sector, there are inherent risks such as systemic, clinical, regulatory, and commercial risks, as well as the need for significant capital to continue developing its pipeline.

Bears say

Nuvalent is downgraded to NEUTRAL due to their proposed acquisition by GSK for $124/share, which is a fair valuation based on their NPV and uncertainties around the positioning of their products. Despite little FTC risk and expected support from shareholders, the long timeline to resolving key investor debates and the lower premium to last closing price and VWAP may limit potential gains for investors.

Nuvalent (NUVL) has been analyzed by 19 analysts, with a consensus rating of Buy. 16% of analysts recommend a Strong Buy, 32% recommend Buy, 53% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvalent and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvalent (NUVL) Forecast

Analysts have given Nuvalent (NUVL) a Buy based on their latest research and market trends.

According to 19 analysts, Nuvalent (NUVL) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $129.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $129.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvalent (NUVL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.